ACE OncoCast

Targeted Therapy in Early-Stage EGFR-Mutated NSCLC

ACE Oncology Season 5 Episode 1

In this episode, lung cancer experts discuss the treatment approach for patients with early-stage, resectable NSCLC who  harbor EGFR sensitizing mutations. Listen to the latest clinical trial data on the use of adjuvant targeted therapy for this patient population.